Tesofensine Dosing Protocol
Tesofensine is an oral triple monoamine reuptake inhibitor (serotonin, norepinephrine, dopamine) originally developed for neurological conditions and later studied for weight loss. Phase 2 trials showed significant weight reduction through appetite suppression and increased energy expenditure.
Key Points
Step-by-Step Guide
Understand Dosing Range
Phase 2 trials tested 0.25 mg, 0.5 mg, and 1.0 mg daily oral doses. The 0.5 mg dose showed the best efficacy-to-side-effect ratio with ~10% body weight loss over 24 weeks.
Start Low
Begin at 0.25 mg daily to assess cardiovascular tolerability. Heart rate and blood pressure increases are dose-dependent and must be monitored.
Escalate Cautiously
After 2-4 weeks at 0.25 mg with acceptable vital signs, consider increasing to 0.5 mg daily. The 1.0 mg dose produced more weight loss but significantly more cardiovascular effects.
Monitor Cardiovascular Parameters
Check resting heart rate and blood pressure weekly during titration, then biweekly. Heart rate increases of 5-10 bpm are typical. Blood pressure may increase modestly.
Assess at 12 Weeks
Evaluate weight loss, appetite changes, mood, sleep quality, and cardiovascular parameters. Continue if benefit outweighs risk; discontinue if cardiovascular effects are concerning.
Warnings & Precautions
- !Not FDA-approved—development ongoing for some indications.
- !Increases heart rate and blood pressure dose-dependently.
- !Contraindicated in uncontrolled hypertension or cardiovascular disease.
- !Monoamine reuptake inhibition may cause insomnia, anxiety, or mood changes.
Frequently Asked Questions
How does tesofensine cause weight loss?
It inhibits reuptake of serotonin, norepinephrine, and dopamine, suppressing appetite while increasing basal energy expenditure. The dual mechanism produces significant caloric deficit.
Is tesofensine safe for the heart?
Cardiovascular effects (increased heart rate and blood pressure) are the primary safety concern. The 0.5 mg dose produces modest increases that most healthy individuals tolerate. It is contraindicated in those with cardiovascular disease.
How does tesofensine compare to GLP-1 agonists?
Tesofensine works through a completely different mechanism (monoamine reuptake) vs. incretin pathways. GLP-1 agonists have far more clinical evidence and FDA approval. Tesofensine may eventually serve as an alternative or adjunct for non-responders.